10-Q: bioAffinity Technologies Reports Second Quarter 2024 Results, Revenue Growth Driven by Lab Services Acquisition

bioAffinity Technologies reports a net loss of $2.1 million for Q2 2024, with significant revenue growth driven by the acquisition of Precision Pathology Laboratory Services.

Summary

• bioAffinity Technologies reported a net loss of $2.1 million for the three months ended June 30, 2024, compared to a net loss of $1.7 million for the same period in 2023.
• The company's revenue increased significantly to $2.4 million in Q2 2024, up from $19,738 in Q2 2023, primarily due to the acquisition of Precision Pathology Laboratory Services (PPLS).
• Operating expenses totaled $4.5 million in Q2 2024, compared to $1.8 million in Q2 2023, with increases across all categories, including direct costs, research and development, and selling, general, and administrative expenses.
• For the six months ended June 30, 2024, the net loss was $4.1 million, compared to $3.3 million for the same period in 2023.
• Revenue for the first six months of 2024 was $4.8 million, compared to $20,659 for the same period in 2023.
• The company's cash and cash equivalents were $0.8 million as of June 30, 2024, and management has expressed substantial doubt about the company's ability to continue as a going concern.
• Subsequent to the quarter end, on August 2, 2024, the company raised an additional $1.7 million through warrant exercises and a securities purchase agreement.

Sentiment

Score: 3

Explanation: The document highlights significant revenue growth due to an acquisition, but the substantial net losses, weak cash position, and going concern warning create a negative outlook. The need for additional capital and the uncertainty surrounding future funding are major concerns.

Positives

• The acquisition of PPLS has significantly increased revenue streams, with patient service fees contributing the majority of the revenue.
• The company has successfully raised additional capital of $1.7 million after the end of the reporting period.
• The company is actively working to expand the commercialization of its CyPath Lung test.

Negatives

• The company experienced a net loss of $2.1 million in Q2 2024 and $4.1 million for the first six months of 2024.
• Operating expenses have increased significantly due to the PPLS acquisition and increased personnel costs.
• The company's cash position is weak, with only $0.8 million in cash and cash equivalents as of June 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and generate revenue.
• The company is incurring significant operating losses and negative cash flows.
• There is no guarantee that the company will be able to obtain additional funding or generate sufficient revenue to achieve profitability.
• The company's business plan relies on the successful development and commercialization of its diagnostic tests and therapeutic products, which are subject to various risks and uncertainties.
• The company's management owns a substantial percentage of the common stock, which could prevent investors from affecting matters involving the company.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future as it continues the development of its diagnostic tests and advances them through clinical trials. The company anticipates raising additional cash through the sale of equity or debt securities, collaborative arrangements, or a combination thereof to continue to fund its operations and develop its products. There is no assurance that any such collaborative arrangement will be entered into or that financing will be available to the company when needed.

Management Comments

• Management concludes that there is substantial doubt about the company's ability to continue as a going concern for a period of at least twelve months subsequent to the issuance of the financial statements.
• Management anticipates that the company's cash resources are sufficient to continue operations through October 2024 without additional funding.

Industry Context

The company operates in the biotechnology and diagnostics industry, focusing on early cancer detection. The acquisition of PPLS is a strategic move to control the laboratory where its CyPath Lung test is processed. The company is also pursuing regulatory approvals for its diagnostic tests and developing therapeutic products, which are common activities in this industry.

Comparison to Industry Standards

• The company's revenue growth is significant compared to the previous year, but this is largely due to the acquisition of PPLS, which is not a direct comparison to organic growth.
• The company's net losses are substantial, which is not uncommon for early-stage biotech companies, but the level of losses and the going concern warning are concerning.
• The company's cash position is weak compared to industry standards, and the need for additional capital is a significant risk.
• Comparable companies in the diagnostic space include Exact Sciences and Guardant Health, which have significantly higher revenue and market capitalization, but also have higher operating expenses and may not be profitable.
• The company's reliance on external funding is typical for biotech companies, but the level of uncertainty about future funding is a significant concern.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the going concern warning.
• Employees may be concerned about job security due to the company's financial situation.
• Customers may be concerned about the company's ability to continue providing services.
• Creditors face increased risk of non-payment due to the company's financial instability.

Next Steps

• The company needs to secure additional funding to continue operations.
• The company needs to continue to expand the commercialization of its CyPath Lung test.
• The company needs to pursue regulatory approvals for its diagnostic tests.
• The company needs to develop and commercialize its therapeutic products.

Key Dates

Keywords

bioAffinity Technologies, CyPath Lung, Precision Pathology Laboratory Services, PPLS, diagnostic tests, lung cancer, clinical trials, revenue, operating expenses, net loss, going concern, warrants, capital raise